C1 Gene Expression Platform - Develop Stable rVaccine & mAb Cell Lines In 2 Months at g/l Yields with High & Rapid Purification

C1 Gene Expression Platform - Develop Stable rVaccine & mAb Cell Lines In 2 Months at g/l Yields with High & Rapid Purification

Tuesday, September 29, 2020 8:50 PM to 9:05 PM · 15 min. (Africa/Abidjan)

One Health & Veterinary Biologics

Biotech

Information

Topics

Topics

COVID-19Vaccine Manufacturing

Dyadic InternationalDyadic International, Inc.– We are a global biotechnology company focused on further improving and leveraging the patented and proprietary C1 expression system to help bring biologic vaccines and drugs to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers to improve access and cost to both the human and animal healthcare industry.

Log in

See all the content and easy-to-use features by logging in